Table 2 Characteristics of patients with DPYD variant results
| Â | DPYD variant N (%) | DPYD wildtype N (%) | Total N (%) |
|---|---|---|---|
Total | 33 (8.9) | 337 (91.1) | 370 (100) |
Treatment intent | |||
 Curative | 19 (57.6) | 188 (5.6) | 207 (55.9) |
 Palliative | 14 (42.4) | 149 (44.1) | 153 (41.4) |
Line of treatment | |||
 First line | 33 (100) | 326 (96.4) | 359 (97.0) |
 Second line | 0 (0) | 11 (3.3) | 11 (3.0) |
Median BSA m2 (25–75% IQR) | 1.9 (1.8–2.1) | 1.9 (1.7–2.0) | 1.9 (1.7–2.0) |
Mean relative initial dose intensity (range) | 54.2% (37.5–75) | 93.2% (42.9–100) | 89.6% (38–100) |
c.1905+1G > A (n = 3) | 50% (50–50) |  |  |
c.2846A> T (n = 4) | 50% (50–50) |  |  |
c.1679T > G (n = 1) | 50% |  |  |
c.1236G> A (n = 9) | 58.3% (50–75) |  |  |
c.1601G> A (n = 13) a | 53.1% (37.5–75%) |  |  |
Chemotherapy | |||
 Single agent | 9 (27.3) | 83 (24.6) | 92 (24.9) |
 Doublet | 21 (63.6) | 198 (58.6) | 219 (59.2) |
 Triplet | 3 (9.1) | 56 (16.6) | 59 (15.9) |
 Anti-VEGF | 0 (0) | 6 (1.8) | 6 (1.6) |
 Anti-EGFR | 1 (3) | 19 (5.6) | 20 (5.4) |
 Trastuzumab | 1 (3) | 5 (1.5) | 6 (1.6) |
 Anti-PD1/PDL1 | 0 (0) | 6 (1.8) | 6 (1.6) |
 Chemoradiotherapy | 6 (18.2) | 58 (17.2) | 64 (17.3) |
Fluoropyrimidine | |||
 5FU | 8 (24.2) | 126 (37.4) | 134 (36.2) |
 Capecitabine | 25 (75.8) | 211 (62.6) | 236 (63.8) |